Ensign Peak Advisors Inc Purchases New Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Ensign Peak Advisors Inc purchased a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 190,557 shares of the company's stock, valued at approximately $3,047,000. Ensign Peak Advisors Inc owned about 0.36% of Tyra Biosciences at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of TYRA. Kynam Capital Management LP purchased a new position in shares of Tyra Biosciences in the fourth quarter worth $4,712,000. Wellington Management Group LLP increased its position in Tyra Biosciences by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company's stock valued at $1,419,000 after acquiring an additional 8,324 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Tyra Biosciences during the first quarter valued at $977,000. Vanguard Group Inc. increased its position in Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock valued at $14,757,000 after acquiring an additional 140,833 shares during the last quarter. Finally, BVF Inc. IL increased its position in Tyra Biosciences by 70.1% during the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company's stock valued at $76,444,000 after acquiring an additional 1,921,599 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wedbush reiterated an "outperform" rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Thursday, August 8th. HC Wainwright reiterated a "buy" rating and set a $23.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Piper Sandler started coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an "overweight" rating and a $33.00 price objective for the company. Finally, Oppenheimer boosted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a report on Thursday, September 19th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $26.40.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $23.40 on Friday. The stock has a 50-day simple moving average of $21.55 and a two-hundred day simple moving average of $18.84. Tyra Biosciences, Inc. has a 52-week low of $10.38 and a 52-week high of $25.14. The firm has a market capitalization of $1.24 billion, a PE ratio of -13.93 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.09. Equities analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

Insider Transactions at Tyra Biosciences

In other news, CEO Todd Harris sold 10,092 shares of the company's stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $24.13, for a total value of $243,519.96. Following the completion of the transaction, the chief executive officer now owns 1,479,528 shares of the company's stock, valued at $35,701,010.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 16,390 shares of company stock valued at $396,444 over the last 90 days. Company insiders own 15.40% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.